Ionis Pharmaceuticals (IONS) announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome, a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals Holds Annual Stockholders Meeting
- Ionis Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Trial Results and Future Prospects
- Cautious Optimism for Ionis Pharmaceuticals Amid Promising Olezarsen Data and Awaited CORE/CORE2 Insights
- Promising Phase 3 Results and Future Prospects of Tryngolza Drive Buy Rating for Ionis Pharmaceuticals
- Ionis Pharmaceuticals’ Promising Future: Buy Rating Backed by Positive Phase 3 Study Results and Upcoming Milestones